Literature DB >> 21529918

Low plasma progesterone concentrations are accompanied by reduced luteal blood flow and increased size of the dominant follicle in dairy cows.

J Lüttgenau1, N Beindorff, S E Ulbrich, J P Kastelic, H Bollwein.   

Abstract

To investigate the influence of low plasma progesterone (P(4)) concentrations on luteal and ovarian follicular development as well as endometrial gene expression in the concomitant and subsequent estrous cycle, 20 lactating dairy (Holstein Friesian and Brown Swiss x Holstein Friesian) cows received either a single treatment with 25 mg prostaglandin F(2α) (PGF(2α)) on Day 4 Hour 12 (PG1; n = 8), or two treatments (25 mg PGF(2α) each) on Day 4 Hours 0 and 12 (PG2; n = 12) of the estrous cycle (Day 1, Hour 0 = ovulation). In four cows, ovulation occurred between 4 and 6 d after the second PGF(2α) treatment; these cows and one lame cow were excluded. In the 15 remaining cows with physiological interovulatory intervals (18 to 24 d), P(4), luteal size (LS) and blood flow (LBF), as well as follicular size (FS) and blood flow (FBF), were determined daily until Day 4, immediately prior to (0 h) and 12 h after each PGF(2α) treatment, and then every 2 d, from Day 5 to 8 d after the subsequent ovulation. Because P(4) did not differ (P > 0.05) between PG1 and PG2, cows were regrouped according to their mean P(4) concentration from Days 7 to 15, either P(4) <2 ng/mL (P(4)L; n = 7) or P(4) >2 ng/mL (P(4)H; n = 8). In the treatment cycle, LS was smaller in P(4)L than P(4)H on Days 13 (P = 0.01) and 15 (P = 0.03), and LBF was lower in P(4)L than P(4)H on Day 15 (P = 0.02). The dominant follicle of the first follicular wave was larger in P(4)L than P(4)H on Days 13 (P = 0.03), 15 (P = 0.03), and 17 (P = 0.01). In the subsequent cycle, there were no significant differences between P(4)L and P(4)H for P(4), FS, LS, and LBF; however, FBF was lower (P = 0.01) in P(4)L than P(4)H on Day 7. In Group P(4)L, endometrial expressions of estrogen receptor α and oxytocin receptor were lower (P = 0.05 and P = 0.03, respectively) at the estrus that preceded treatment compared to the post-treatment estrus. In summary, low P(4) during diestrus was associated with smaller LS, reduced LBF, and larger FS in the treatment cycle, but not in the subsequent cycle.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529918     DOI: 10.1016/j.theriogenology.2010.12.025

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  4 in total

1.  Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation.

Authors:  Annunziata Mauro; Alessandra Martelli; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Oriana Di Giacinto; Mauro Mattioli; Barbara Barboni
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

2.  Inhibition of lipopolysaccharide-induced suppression of luteal function in isolated perfused bovine ovaries.

Authors:  Elena Storni; Heinrich Bollwein; Anna-Katharina Hankele; Olga Wellnitz; Rupert M Bruckmaier; Susanne E Ulbrich; Johannes Lüttgenau
Journal:  J Reprod Dev       Date:  2021-11-02       Impact factor: 2.214

3.  Characterization of blood flow and the effects of exogenous estradiol benzoate on residual follicles formed after ultrasound-guided transvaginal follicle aspiration in cattle.

Authors:  Alberto Mansur Ghetti; Luiz Gustavo Bruno Siqueira; Eduardo Kenji Nunes Arashiro; Miller Pereira Palhao; Felipe Zandonadi Brandao; Joao Henrique Moreira Viana
Journal:  J Anim Sci Biotechnol       Date:  2016-10-06

4.  Effects of P4 Antagonist RU486 on VEGF and Its Receptors' Signaling during the In Vivo Transition from the Preovulatory to Periovulatory Phase of Ovarian Follicles.

Authors:  Annunziata Mauro; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Alessandra Martelli; Delia Nardinocchi; Oriana Di Giacinto; Maura Turriani; Barbara Barboni
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.